Synonyms: IL17-MS3086 | IL17MS3086 | SEQ ID 836 [WO2012156219A1]
Compound class:
Antibody
Comment: Sonelokimab (IL17MS3086) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. IL17MS3086 potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential. We provide the IL17MS3086 to sonelokimab association in good faith, and await formal disclosure.
|
Bioactivity Comments |
IL17MS3086 binds human and cynomolgus recombinant IL-17 A and -F with no significant difference in binding affinities, and binds to marmoset versions of the cytokines, but it does not bind mouse or rat IL-17 A or -F [1]. IL17MS3086 prevents hIL-17A/F-induced cytokine release in mouse serum [1]. Kd values in the interaction table were determined using a Myc-His tagged version of IL17MS3086 (known as IL17MS3091 in the patent) and are expected to be little different for the parent nanobody. |
Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|